Show simple item record

dc.contributor.authorAdamski, Piotr
dc.contributor.authorBuszko, Katarzyna
dc.contributor.authorSikora, Joanna
dc.contributor.authorNiezgoda, Piotr
dc.contributor.authorBarańska, Malwina
dc.contributor.authorOstrowska, Małgorzata
dc.contributor.authorPaciorek, Przemysław
dc.contributor.authorNavarese, Eliano P
dc.contributor.authorGorog, Diana
dc.contributor.authorKubica, Jacek
dc.date.accessioned2019-04-23T14:05:18Z
dc.date.available2019-04-23T14:05:18Z
dc.date.issued2018-09-06
dc.identifier.citationAdamski , P , Buszko , K , Sikora , J , Niezgoda , P , Barańska , M , Ostrowska , M , Paciorek , P , Navarese , E P , Gorog , D & Kubica , J 2018 , ' Metabolism of ticagrelor in patients with acute coronary syndromes. ' , Scientific Reports , vol. 8 , 11746 , pp. 1-8 . https://doi.org/10.1038/s41598-018-29619-9
dc.identifier.issn2045-2322
dc.identifier.otherPURE: 16605134
dc.identifier.otherPURE UUID: 0b8d0ead-0f29-41e5-99a0-5a2b689bf0d7
dc.identifier.otherScopus: 85051163867
dc.identifier.urihttp://hdl.handle.net/2299/21292
dc.description© The Author(s) 2018
dc.description.abstractTicagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized by hepatic CYP3A enzymes, and AR-C124910XX is its only active metabolite. A post hoc analysis of patient-level (n = 117) pharmacokinetic data pooled from two prospective studies was performed to identify clinical characteristics affecting the degree of AR-C124910XX formation during the first six hours after 180 mg ticagrelor loading dose in the setting of ACS. Both linear and multiple regression analyses indicated that ACS patients presenting with ST-elevation myocardial infarction or suffering from diabetes mellitus are more likely to have decreased rate of ticagrelor metabolism during the acute phase of ACS. Administration of morphine during ACS was found to negatively influence transformation of ticagrelor into AR-C124910XX when assessed with linear regression analysis, but not with multiple regression analysis. On the other hand, smoking appears to increase the degree of ticagrelor transformation in ACS patients. Mechanisms underlying our findings and their clinical significance warrant further research.en
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofScientific Reports
dc.rightsOpen
dc.titleMetabolism of ticagrelor in patients with acute coronary syndromes.en
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2018-09-06
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1038/s41598-018-29619-9
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record